Among the current exclusion criteria for treatment with GH are untreated severe OSA and severe obesity, and it is recommended that individuals with PWS complete a polysomnography study prior to starting GH therapy [58,59]. This evidence concerns the gene GH1 and obesity due to melanocortin 4 receptor deficiency.